We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
1ADNB | AdAlta Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
1ADO | AdAlta Limited | 0.002 | 0.00 | 0.00% | 0.00 | 0 |
1ADOA | AdAlta Limited | 0.002 | 0.00 | 0.00% | 0.00 | 0 |
1AE | Aurora Energy Metals Ltd | 0.089 | 0.00 | 0.00% | 0.00 | 0 |
1ADNA | AdAlta Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
1ADN | AdAlta Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
14D | 1414 Degrees Limited | 0.071 | 0.00 | 0.00% | 0.00 | 0 |
14DN | 1414 Degrees Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
14DO | 1414 Degrees Limited | 0.008 | 0.00 | 0.00% | 0.00 | 0 |
1AD | AdAlta Limited | 0.027 | 0.00 | 0.00% | 0.00 | 0 |
13S | 13 Seeds Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders, defined as one that affects fewer than 200,000 people in the U.S. In addition to providing a seven-year term of market exclusivity upon final FDA approval, orphan drug designation also positions Soligenix to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a Biologics License Application (BLA), and certain tax credits.
RADNOR, Pa., April 17, 2024 /PRNewswire/ --Â NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
HONG KONG, April 17, 2024 /PRNewswire/ -- ICZOOM Group Inc. (Nasdaq: IZM) (the "Company" or "ICZOOM"), announced today that it voluntarily requested a withdrawal of a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (File No.333-275708, the "Registration Statement") and accordingly cancelled the proposed public offering pursuant to the Registration Statement .
AIRPORT CITY, Israel, April 15, 2024 /PRNewswire/ -- MySize, Inc. (NASDAQ:Â MYSZ) ("MySize" or the "Company"), an omnichannel e-commerce platform and provider of AI-driven measurement solutions to drive revenue growth and reduce costs for its business clients, announced that its Board of Directors has approved a one-for-eight reverse stock split of its common stock that is scheduled to become effective after trading closes on April 19, 2024. Beginning on April 23, 2024, the Company's common stock will trade on the Nasdaq Capital Market on a split adjusted basis under a new CUSIP number 62844N 406. The Company's common stock will continue ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 61,447.50 | -2,404.33 | -3.77% | 1.19T | 7,150,920,844 |
ETH | Ethereum | 3,000.09 | -84.73 | -2.75% | 357.3B | 3,060,912,000 |
USDT | Tether USD | 0.9999 | -0.0001 | -0.01% | 97.84B | 443,173,026 |
BNB | Binance Coin | 537.44 | -0.700784 | -0.13% | 84.48B | 467,946,618 |
SOL | Solana | 135.16 | -1.25 | -0.92% | 58.87B | 2,142,431,839 |
STETH | stETH | 2,996.20 | -68.08 | -2.22% | 29.1B | 16,345,765 |
USDC | USD Coin | 0.9999 | -0.0001 | -0.01% | 28.07B | 1,227,656,387 |
XRP | Ripple | 0.4946 | -0.0021 | -0.42% | 26.78B | 444,042,553 |
TONCOIN | Wrapped TON Coin | 6.12 | -0.231472 | -3.64% | 21.02B | 224,211,449 |
DOGE | Dogecoin | 0.14869 | -0.00736 | -4.72% | 21.02B | 639,490,361 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions